Influence of cantonal health policy frameworks & amp; activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland
CONCLUSION: There was no association between the investigated cantonal frameworks and number of health activities and influenza vaccination coverage in NCD patients in the selected cantons. However, age, disease status and linguistic region appear to have an influence on vaccination uptake.PMID:36154757 | DOI:10.1016/j.vaccine.2022.09.038 (Source: Vaccine)
Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Lisa Ruckstuhl Astrid Czock Sarah R Haile Phung Lang Source Type: research

A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease
Vaccine. 2022 Sep 22:S0264-410X(22)01100-8. doi: 10.1016/j.vaccine.2022.09.006. Online ahead of print.ABSTRACTSystemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination...
Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Vincent P Kuiper Pauline van der Plas Marie-Astrid Hoogerwerf Jan Pieter R Koopman Andrea E van der Meulen Anna H E Roukens Leo G Visser Meta Roestenberg Source Type: research

The human immune response to vaccines is symphonic, polyphonic, homophonic, and megaphonic
Vaccine. 2022 Sep 23:S0264-410X(22)01099-4. doi: 10.1016/j.vaccine.2022.09.005. Online ahead of print.NO ABSTRACTPMID:36163091 | DOI:10.1016/j.vaccine.2022.09.005 (Source: Vaccine)
Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Gregory A Poland Source Type: research

How health workers can make a difference in the public COVID-19 vaccination response
Vaccine. 2022 Sep 6:S0264-410X(22)01081-7. doi: 10.1016/j.vaccine.2022.08.074. Online ahead of print.NO ABSTRACTPMID:36163092 | DOI:10.1016/j.vaccine.2022.08.074 (Source: Vaccine)
Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Katrine B Habersaat Sideeka Narayan Siff Malue Nielsen Martha Scherzer Cristiana Salvi Holly Seale Source Type: research

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
CONCLUSIONS: Among immunocompromised adults, a 2-dose mRNA-1273 regimen was more effective in preventing medically-attended COVID-19 in any setting (inpatient and outpatient) than 2-dose BNT162b2. Results were similar for COVID-19 hospitalization, although statistical power was limited when using closed claims only.STUDY REGISTRATION: NCT05366322.PMID:36163093 | DOI:10.1016/j.vaccine.2022.09.025 (Source: Vaccine)
Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Katherine E Mues Brenna Kirk Deesha A Patel Alice Gelman L Scott Chavers Carla A Talarico Daina B Esposito David Martin James Mansi Xing Chen Nicolle M Gatto Nicolas Van de Velde Source Type: research

Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses
Vaccine. 2022 Sep 21:S0264-410X(22)01045-3. doi: 10.1016/j.vaccine.2022.08.052. Online ahead of print.ABSTRACTWe undertook a Phase 4 clinical trial to assess the effect of time interval between booster doses on serological responses to AVP. The primary objective was to evaluate responses to a single booster dose in two groups of healthy adults who had previously received a complete 4-dose primary course. Group A had received doses on schedule while Group B had not had one for ≥2 years. Secondary objectives were to evaluate the safety and tolerability of AVP booster doses, and to gain information on correlates of protecti...
Source: Vaccine - September 24, 2022 Category: Allergy & Immunology Authors: E Hugh Dyson Andrew J H Simpson Robert J Gwyther Hannah Cuthbertson Dawn H Patient Mary Matheson Anya Gregg Matthew J Hepburn Bassam Hallis E Diane Williamson Source Type: research

Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses
Vaccine. 2022 Sep 21:S0264-410X(22)01045-3. doi: 10.1016/j.vaccine.2022.08.052. Online ahead of print.ABSTRACTWe undertook a Phase 4 clinical trial to assess the effect of time interval between booster doses on serological responses to AVP. The primary objective was to evaluate responses to a single booster dose in two groups of healthy adults who had previously received a complete 4-dose primary course. Group A had received doses on schedule while Group B had not had one for ≥2 years. Secondary objectives were to evaluate the safety and tolerability of AVP booster doses, and to gain information on correlates of protecti...
Source: Vaccine - September 24, 2022 Category: Allergy & Immunology Authors: E Hugh Dyson Andrew J H Simpson Robert J Gwyther Hannah Cuthbertson Dawn H Patient Mary Matheson Anya Gregg Matthew J Hepburn Bassam Hallis E Diane Williamson Source Type: research

Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers
CONCLUSIONS: Hybrid immunity confers higher protection by almost 5-fold compared to full or booster vaccination for COVID-19 infection with the Omicron variant among HCWs who are at high risk of exposure. This may inform public health policies on how to achieve optimal immunity in terms of the timing and mode of vaccination.PMID:36150972 | PMC:PMC9482842 | DOI:10.1016/j.vaccine.2022.09.042 (Source: Vaccine)
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Fotinie Ntziora Evangelia Georgia Kostaki Amalia Karapanou Maria Mylona Ioulia Tseti Nikolaos V Sipsas Dimitrios Paraskevis Petros P Sfikakis Source Type: research

Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Vaccine. 2022 Sep 20:S0264-410X(22)01085-4. doi: 10.1016/j.vaccine.2022.09.001. Online ahead of print.ABSTRACTThis is a Brighton Collaboration case definition of thrombosis and thromboembolism to be used in the evaluation of adverse events following immunization, and for epidemiologic studies for the assessment of background incidence or hypothesis testing. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of SARS-CoV-2 vaccines. The case definition format of the Brighton Collaboration was followed to develop a...
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Jahnavi Gollamudi Sarah E Sartain Amir Hassan Navaei Satinder Aneja Pawandeep Kaur Dhawan Dat Tran Jyoti Joshi Jane Gidudu Jayakrishna Gollamudi Elena Chiappini Frederick Varricchio Barbara Law Flor M Munoz Source Type: research

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)
CONCLUSIONS: Catch-up vaccination with V114 in healthy individuals 7 months-17 years of age was generally well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of prior pneumococcal vaccination. These results support V114 catch-up vaccination in children with incomplete or no PCV immunization per the recommended schedule.PMID:36150974 | DOI:10.1016/j.vaccine.2022.09.003 (Source: Vaccine)
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Natalie Banniettis Jacek Wysocki Leszek Szenborn Wanatpreeya Phongsamart Punnee Pitisuttithum Mika R ämet Peter Richmond Yaru Shi Ron Dagan Lori Good Melanie Papa Robert Lupinacci Richard McFetridge Gretchen Tamms Clay Churchill Luwy Musey Kara Bickham V Source Type: research

Immunity of two novel hepatitis C virus polyepitope vaccines
In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2384-411aa)-Bp (E1313-327aa-E2396-424aa-E2436-447aa-E2523-540aa-E2610-627aa-E2631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of L...
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Tian Feng Mingzhi Li Lirong Zhang Sha Li Zibing Yang Lumei Kang Yunli Guo Lingbao Kong Ting Wang Source Type: research

Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers
CONCLUSIONS: Hybrid immunity confers higher protection by almost 5-fold compared to full or booster vaccination for COVID-19 infection with the Omicron variant among HCWs who are at high risk of exposure. This may inform public health policies on how to achieve optimal immunity in terms of the timing and mode of vaccination.PMID:36150972 | DOI:10.1016/j.vaccine.2022.09.042 (Source: Vaccine)
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Fotinie Ntziora Evangelia Georgia Kostaki Amalia Karapanou Maria Mylona Ioulia Tseti Nikolaos V Sipsas Dimitrios Paraskevis Petros P Sfikakis Source Type: research

Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Vaccine. 2022 Sep 20:S0264-410X(22)01085-4. doi: 10.1016/j.vaccine.2022.09.001. Online ahead of print.ABSTRACTThis is a Brighton Collaboration case definition of thrombosis and thromboembolism to be used in the evaluation of adverse events following immunization, and for epidemiologic studies for the assessment of background incidence or hypothesis testing. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of SARS-CoV-2 vaccines. The case definition format of the Brighton Collaboration was followed to develop a...
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Jahnavi Gollamudi Sarah E Sartain Amir Hassan Navaei Satinder Aneja Pawandeep Kaur Dhawan Dat Tran Jyoti Joshi Jane Gidudu Jayakrishna Gollamudi Elena Chiappini Frederick Varricchio Barbara Law Flor M Munoz Source Type: research

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)
CONCLUSIONS: Catch-up vaccination with V114 in healthy individuals 7 months-17 years of age was generally well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of prior pneumococcal vaccination. These results support V114 catch-up vaccination in children with incomplete or no PCV immunization per the recommended schedule.PMID:36150974 | DOI:10.1016/j.vaccine.2022.09.003 (Source: Vaccine)
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Natalie Banniettis Jacek Wysocki Leszek Szenborn Wanatpreeya Phongsamart Punnee Pitisuttithum Mika R ämet Peter Richmond Yaru Shi Ron Dagan Lori Good Melanie Papa Robert Lupinacci Richard McFetridge Gretchen Tamms Clay Churchill Luwy Musey Kara Bickham V Source Type: research

Immunity of two novel hepatitis C virus polyepitope vaccines
In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2384-411aa)-Bp (E1313-327aa-E2396-424aa-E2436-447aa-E2523-540aa-E2610-627aa-E2631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of L...
Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Tian Feng Mingzhi Li Lirong Zhang Sha Li Zibing Yang Lumei Kang Yunli Guo Lingbao Kong Ting Wang Source Type: research